Milada Zemanová
YOU?
Author Swipe
View article: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study Open
PURPOSE Immunotherapy targeting PD-L1 improves outcomes in patients with unresectable stage III non–small cell lung cancer (NSCLC) and no progression after definitive, concurrent chemoradiotherapy (cCRT). Earlier administration of immunoth…
View article: Nutrition of children up to one year of age what public health topic
Nutrition of children up to one year of age what public health topic Open
Background Nutrition is one of the most important factors for a person that affects the quality and length of life. Nutrition has a fundamental influence on the maintenance of health or the development of disease and participates in the co…
View article: Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Open
PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NS…
View article: LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2
LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2 Open
The PACIFIC trial established consolidation durvalumab (D) after chemoradiotherapy (CRT) as SoC for pts with unresectable stage III NSCLC. However, up to 30% of pts are ineligible due to progression during/shortly after CRT or inadequate r…
View article: 1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04) Open
View article: Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 Open
View article: 419. PROGNOSTIC RELEVANCE OF METABOLIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR ADENOCARCINOMA OF THE ESOPHAGUS AND ESOPHAGOGASTRIC JUNCTION
419. PROGNOSTIC RELEVANCE OF METABOLIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR ADENOCARCINOMA OF THE ESOPHAGUS AND ESOPHAGOGASTRIC JUNCTION Open
Background The prognostic value of the metabolic response to neoadjuvant therapy in patients with adenocarcinoma of the esophagus and esophagogastric junction (EAC) remains controversial. The aim of our single-center prospective trial was …
View article: Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer
Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer Open
ClinicalTrials.gov Identifier: NCT02111577.
View article: Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment Open
View article: The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma – review
The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma – review Open
Evaluation of an early PET-based response has the potential to modify the treatment in patients who have not demonstrated an early response to CHMT. However, this is not an approach suitable for routine practice outside of clinical trials.…
View article: Real-life Effectiveness of Afatinib <i>Versus</i> Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
Real-life Effectiveness of Afatinib <i>Versus</i> Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study Open
Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
View article: Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial Open
View article: Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction
Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction Open
We prospectively investigated whether metabolic response assessed by 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (PET/CT) early in the course of neoadjuvant chemotherapy is predictive of survival i…
View article: Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors Open
mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
View article: PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study
PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study Open
Background: Perioperative chemotherapy is a recommended treatment approach for localised oesophago-gastric junction adenocarcinoma, but not all patients respond to neoadjuvant chemotherapy. Early identification of non-responders and treatm…
View article: Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial Open
DCVAC/LuCa in combination with carboplatin and paclitaxel extended OS and was well tolerated.
View article: Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Open
View article: Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe
Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe Open
Background The aim of this project was to collect real-world evidence and describe treatment patterns for stage III non-small cell lung cancer in Central and Eastern Europe. Based on real-world evidence, an expert opinion was developed, an…
View article: Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry Open
The role of cytoreductive nephrectomy (CN) in treatment of locally advanced or metastatic renal cell carcinoma (mRCC) in the era of targeted therapies (TT) is still not clearly defined. The study population consisted of 730 patients with s…
View article: Real‐life effectiveness of first‐line anticancer treatments in stage <scp>IIIB</scp>/<scp>IV NSCLC</scp> patients: Data from the <scp>C</scp>zech <scp>TULUNG R</scp>egistry
Real‐life effectiveness of first‐line anticancer treatments in stage <span>IIIB</span>/<span>IV NSCLC</span> patients: Data from the <span>C</span>zech <span>TULUNG R</span>egistry Open
Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line t…
View article: Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience
Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience Open
Background Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-…
View article: Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer Open
The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The pres…
View article: Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients Open
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from l…
View article: Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis Open
Background Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug re…
View article: P2.14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic
P2.14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic Open
View article: Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC) Open
View article: Effect and Toxicity of Radiation Therapy in Selected Palliative Indications
Effect and Toxicity of Radiation Therapy in Selected Palliative Indications Open
Palliative RT provided excellent symptom control in our patients, with minimal toxicity. Thus, RT is an effective and easy-to-use method for many palliative indications. Key words: palliative care - radiotherapy - lung neoplasms - neoplasm…
View article: Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer Open
Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of …
View article: Advances in radiotherapy for lung cancer
Advances in radiotherapy for lung cancer Open
V léčbě plicní rakoviny je základní modalitou radioterapie, která má prokázaný léčebný prospěch v radikálních i paliativních indikacích až u 76 % všech nemocných.V České republice dlouhodobě nepřekračuje podíl nemocných s bronchogenním kar…
View article: Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients Open
The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and…